Your browser doesn't support javascript.
loading
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis, U A; Wulf, G M; Barry, W T; Birrer, M; Westin, S N; Farooq, S; Bell-McGuinn, K M; Obermayer, E; Whalen, C; Spagnoletti, T; Luo, W; Liu, H; Hok, R C; Aghajanian, C; Solit, D B; Mills, G B; Taylor, B S; Won, H; Berger, M F; Palakurthi, S; Liu, J; Cantley, L C; Winer, E.
Afiliación
  • Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Wulf GM; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, USA.
  • Barry WT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Birrer M; Department of Hematology and Oncology, Massachusetts General Hospital, Boston, USA.
  • Westin SN; Department of Gynecologic Oncology, MD Anderson Cancer Center, Houston, USA.
  • Farooq S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Bell-McGuinn KM; Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Obermayer E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Whalen C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Spagnoletti T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Luo W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Liu H; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, USA.
  • Hok RC; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, USA.
  • Aghajanian C; Memorial Sloan Kettering Cancer Center, New York, USA.
  • Solit DB; Memorial Sloan Kettering Cancer Center, New York, USA.
  • Mills GB; Department of Systems Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Taylor BS; Memorial Sloan Kettering Cancer Center, New York, USA.
  • Won H; Memorial Sloan Kettering Cancer Center, New York, USA.
  • Berger MF; Memorial Sloan Kettering Cancer Center, New York, USA.
  • Palakurthi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Liu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
  • Cantley LC; Weill Cornell Medical College, New York, USA.
  • Winer E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,USA.
Ann Oncol ; 28(3): 512-518, 2017 03 01.
Article en En | MEDLINE | ID: mdl-27993796
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Neoplasias de la Mama / Morfolinas / Proteína BRCA1 / Proteína BRCA2 / Aminopiridinas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Neoplasias de la Mama / Morfolinas / Proteína BRCA1 / Proteína BRCA2 / Aminopiridinas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido